Angiotensin receptor blockers: A panacea for Marfan syndrome and related disorders?

Drug Discovery Today

Volumn 20, Issue 2, 2015, Pages 262-266

  Loeys, Bart L ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOCKING ANTIBODY; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; FIBRILLIN 1; GELATINASE A; GELATINASE B; INDOMETACIN; IRBESARTAN; LOSARTAN; PRAVASTATIN; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL AORTA ANEURYSM; AORTA DISSECTION; AORTA SURGERY; ARTERIAL STIFFNESS; CARDIOVASCULAR SURGERY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; LOEYS DIETZ SYNDROME; MARFAN SYNDROME; MECHANOTRANSDUCTION; MONOTHERAPY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; THORACIC AORTA ANEURYSM; TREATMENT RESPONSE; ANIMAL;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; HUMANS; LOSARTAN; MARFAN SYNDROME;

EID: 84922956222     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.022     Document Type: Review

References (52)

1. E. Gillis Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-beta signaling and vascular smooth muscle cell contractility Circ. Res. 113 2013 327 340
2. H.C. Dietz Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene Nature 352 1991 337 339
3. D.P. Judge Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome J. Clin. Invest. 114 2004 172 181
4. E.R. Neptune Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome Nat. Genet. 33 2003 407 411
5. J.P. Habashi Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 2006 117 121
6. C.M. Ng TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome J. Clin. Invest. 114 2004 1586 1592
7. R.D. Cohn Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states Nat. Med. 13 2007 204 210
8. J.P. Habashi Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism Science 332 2011 361 365
9. T.M. Holm Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice Science 332 2011 358 361
10. M.E. Lindsay, and H.C. Dietz Lessons on the pathogenesis of aneurysm from heritable conditions Nature 473 2011 308 316
11. B.L. Loeys A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 Nat. Genet. 37 2005 275 281
12. B.L. Loeys Aneurysm syndromes caused by mutations in the TGF-beta receptor N. Engl. J. Med. 355 2006 788 798
13. M.E. Lindsay Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm Nat. Genet. 44 2012 922 927
14. I.M. van de Laar Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis Nat. Genet. 43 2011 121 126
15. I.M. van de Laar Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome J. Med. Genet. 49 2012 47 57
16. E.M. Gallo Angiotensin II-dependent TGF-beta signaling contributes to Loeys-Dietz syndrome vascular pathogenesis J. Clin. Invest. 124 2014 448 460
17. M. Horiguchi Matrix control of transforming growth factor-beta function J. Biochem. 152 2012 321 329
18. A.C. Braverman Timing of aortic surgery in the Marfan syndrome Curr. Opin. Cardiol. 19 2004 549 550
19. C.M. Brophy Propranolol stimulates the crosslinking of matrix components in skin from the aneurysm-prone blotchy mouse J. Surg. Res. 46 1989 330 332
20. J. Shores Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome N. Engl. J. Med. 330 1994 1335 1341
21. D.R. Gersony The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis Int. J. Cardiol. 114 2007 303 308
22. L.F. Hiratzka 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine Circulation 121 2010 e266 e369
23. B.S. Brooke Angiotensin II blockade and aortic-root dilation in Marfan's syndrome N. Engl. J. Med. 358 2008 2787 2795
24. R.E. Pyeritz A small molecule for a large disease N. Engl. J. Med. 358 2008 2829 2831
25. H.H. Chiu Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study Mayo Clin. Proc. 88 2013 271 276
26. C. Pees Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome Am. J. Cardiol. 112 2013 1477 1483
27. M. Groenink Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial Eur. Heart J. 34 2013 3491 3500
28. M.A. Pfeffer Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
29. I. Sipahi Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol. 11 2010 627 636
30. A. Li-Wan-Po Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine Br. J. Clin. Pharmacol. 72 2011 6 17
31. A. Singh, and S. Bangalore Which, if any, antihypertensive agents cause cancer? Curr. Opin. Cardiol. 27 2012 374 380
32. J.R. Cook Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients Mt. Sinai J. Med. 77 2010 366 373
33. T. Yin Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan Hypertens. Res. 31 2008 1549 1557
34. A.A. Ahimastos Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial JAMA 298 2007 1539 1547
35. G. Guo Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment Circulation 114 2006 1855 1862
36. G. Guo Induction of macrophage chemotaxis by aortic extracts from patients with Marfan syndrome is related to elastin binding protein PLoS ONE 6 2011 e20138
37. G. Guo Antagonism of GxxPG fragments ameliorates manifestations of aortic disease in Marfan syndrome mice Hum. Mol. Genet. 22 2013 433 443
38. A.W. Chung Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9 Circ. Res. 102 2008 e73 e85
39. W. Xiong Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome J. Vasc. Surg. 47 2008 166 172 discussion 172
40. H.H. Yang Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome J. Thorac. Cardiovasc. Surg. 140 2010 305 312
41. J.A. Curci Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms J. Vasc. Surg. 31 2000 325 342
42. M. Mosorin Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study J. Vasc. Surg. 34 2001 606 610
43. D. McLoughlin Pravastatin reduces Marfan aortic dilation Circulation 124 2011 S168 S173
44. G.P. Sorice, and F. Folli A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes) Med. Hypotheses 73 2009 614 618
45. R.V. Lacro Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am. Heart J. 154 2007 624 631
46. F.I. Gambarin Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations J. Cardiovasc. Med. 10 2009 354 362
47. D. Detaint Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome Arch. Cardiovasc. Dis. 103 2010 317 325
48. T. Radonic Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial Trials 11 2010 3
49. A. Forteza Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome Rev. Esp. Cardiol. 64 2011 492 498
50. K. Moberg The Ghent Marfan Trial - a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers Int. J. Cardiol. 157 2012 354 358
51. M.J. Mullen A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol Trials 14 2013 408
52. N. Fukuda Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells Am J Hypertens Feb; 13 2000 191 198